FDA warned Apotex again of "serious and repeat" manufacturing violations at two of its plants, saying that the generics maker hasn't done enough to correct problems raised in previous agency warnings. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments